Sales growth is tapering off for this provider of delivery services for transplant organs.From the beginning of 2024 through Aug. 23, shares of TransMedics (TMDX 0.56%) stock soared by 123% -- but the good times didn't last. A third-quarter earnings miss sent shares of the organ-transplant equipment and service provider reeling. By lunchtime on Nov. 7, the stock was 51.5% below its previous peak.Hospitals and organ transplant centers increasingly rely on TransMedics' proprietary organ care system (OCS). Is ...

The organ transplant specialist posted disappointing results in its third-quarter report.Shares of TransMedics (TMDX -1.35%), a biotech company that specializes in organ transportation, were tumbling last month after it issued disappointing results in its third-quarter update.TransMedics shares had been soaring prior to the report as investors saw it as a disruptor in the industry, and it has put up impressive top-line growth.The third-quarter results called the valuation into question as the company's grow ...

TransMedics quickly became the leader in liver, heart, and lung transplants, but its third-quarter earnings left the market worried. Here's why I believe its pullback in share price is an opportunity. TransMedics (TMDX 0.53%) is on a mission to revolutionize the organ transplant process. Thanks to the company's Organ Care System (OCS), TransMedics' equipment essentially keeps donated livers, hearts, and lungs "functioning" as they are en route to their donee. Powered by this incredibly important capability, ...

TransMedics (TMDX) reported $108.76 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 63.7%. EPS of $0.12 for the same period compares to -$0.12 a year ago.The reported revenue represents a surprise of -4.78% over the Zacks Consensus Estimate of $114.22 million. With the consensus EPS estimate being $0.28, the EPS surprise was -57.14%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to d ...

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38891 TransMedics Group, Inc. (Exact name of registrant as specified in its charter) Massachusetts 83-2181531 (State or other ...

My last analysis on TransMedics Group, Inc. (NASDAQ: TMDX ) warned that the upcoming aircraft maintenance challenges and aviation operating expenses would shake investors' confidence at the end of this year. Unfortunately, this also coincided with poor revenue performanceFounder/former executive of private jet airline - 9 figure exit to PE platform. Current CEO of FlyVizor, an aviation business advisory firm and host of The VIP Seat, a weekly business aviation news show available on most streaming platforms ...

TransMedics Group, Inc. (TMDX) reported third-quarter 2024 earnings per share (EPS) of 12 cents, which missed the Zacks Consensus Estimate of 28 cents by 57.1%. The company recorded a loss per share of 78 cents in the year-ago period. TransMedics registered revenues of $108.8 million, up 63.9% year over year. The figure, however, missed the Zacks Consensus Estimate by 4.8%. The year-over-year increase in sales was driven by the increase in utilization of the Organ Care System (OCS) across all three organs a ...

TransMedics Group (NASDAQ: TMDX ) shares are falling about 25% in pre-market hours after an extremely disappointing third-quarter report, which showed Wall Street, and I, got way ahead of ourselves.I aim to invest in companies with perfect qualitative attributes, buy them at an attractive price based on fundamentals, and hold them forever. I hope to publish articles covering such companies approximately 3 times per week, with extensive quarterly follow-ups and constant updates.I manage a concentrated portfo ...

TransMedics Group, Inc. TMDX posted downbeat quarterly results on Monday. TransMedics reported quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 30 cents per share. The company reported quarterly sales of $108.76 million which missed the analyst consensus estimate of $115.00 million. "We are proud of our performance year to date and look forward to ending 2024 on a strong note," said Waleed Hassanein, president and CEO of TransMedics. "We continued to make meaningful pr ...